Skip to main content
. Author manuscript; available in PMC: 2009 Jun 12.
Published in final edited form as: J Mol Biol. 2008 Mar 6;378(3):565–580. doi: 10.1016/j.jmb.2008.02.066

Fig. 7.

Fig. 7

NYAD-1 inhibits HIV-1 but not EIAV particle production. 293T cells transfected with either pNL4-3 (a-c) or pPRE-Gag (d and e) were treated with the indicated concentration of NYAD-1. Peptide-treated cells were metabolically labeled with [35S]Met/Cys for 2 h (HIV-1) or 7-8 h (EIAV). Cells were lysed and virions were pelleted by ultracentrifugation. Cell and virus lysates were immunoprecipitated with HIV-Ig or anti-EIAV antiserum and subjected to SDS-PAGE (a and d); data were quantified by phosphorimager analysis. HIV-1 release efficiency was calculated as the amount of virion-associated p24 relative to total (cell + virion) Gag (b). Accumulation of HIV-1 Pr55Gag in cells was measured by calculating the ratio of Pr55Gag to total Gag in cells (Pr55Gag + p24) (c). EIAV release efficiency was calculated as the amount of virion-associated Pr55Gag to total Pr55Gag in cells and virions (e). For HIV-1 and EIAVassays, n = 4 and n = 3, respectively, with means + SD. The percentages were normalized to untreated levels.